SBFMW Sunshine Biopharma Inc. warrant
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also provides generic prescription drugs for the treatment of breast cancer, prostate cancer, and benign prostatic hyperplasia; and Essential 9, a dietary supplement tablet. Sunshine Biopharma, Inc. has a license agreement with the University of Georgia to advance the development of two anti-coronavirus compounds in parallel with its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. was founded in 2006 and is headquartered in Pointe-Claire, Canada. This security was issued by Sunshine Biopharma Inc., whose common stock symbol is SBFM.
$0.51 0.00 (0.00%)
As of 03/23/2023 00:00:00 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Warrants
Category3: Operating Companies
GICS sector: Health Care
Industry: Drug Manufacturers—Specialty &
Index country: USA
Country of incorporation:
IPO date: 02/15/2022
Outstanding shares: 3,062,546
Average volume: 1,852
Market cap: $17,840,391
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol: